BidaskClub downgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a buy rating to a hold rating in a report published on Saturday, BidAskClub reports.

Other research analysts have also recently issued reports about the company. Morgan Stanley decreased their price target on DBV TECHNOLOGIE/S from $11.00 to $4.00 and set an equal weight rating on the stock in a research note on Wednesday, March 18th. Citigroup cut their price objective on DBV TECHNOLOGIE/S from $14.00 to $10.00 and set a buy rating on the stock in a research report on Monday, April 6th. ValuEngine raised DBV TECHNOLOGIE/S from a hold rating to a buy rating in a research report on Wednesday, March 11th. Stifel Nicolaus reaffirmed a hold rating on shares of DBV TECHNOLOGIE/S in a research report on Friday, June 26th. Finally, Kepler Capital Markets lowered DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research report on Friday, March 20th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. DBV TECHNOLOGIE/S currently has a consensus rating of Buy and a consensus target price of $10.21.

NASDAQ:DBVT opened at $4.63 on Friday. The company has a quick ratio of 3.75, a current ratio of 3.79 and a debt-to-equity ratio of 0.12. The stock’s fifty day moving average is $5.16 and its two-hundred day moving average is $7.37. DBV TECHNOLOGIE/S has a 52 week low of $2.02 and a 52 week high of $13.49. The stock has a market capitalization of $481.14 million, a price-to-earnings ratio of -1.99 and a beta of 2.60.

Hedge funds have recently modified their holdings of the business. Advisor Group Holdings Inc. purchased a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth about $43,000. FinTrust Capital Advisors LLC purchased a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth about $46,000. McAdam LLC purchased a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth about $47,000. Exane Derivatives purchased a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth about $51,000. Finally, Engineers Gate Manager LP purchased a new position in shares of DBV TECHNOLOGIE/S during the first quarter worth about $55,000. 44.00% of the stock is currently owned by institutional investors.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: How can investors invest in the S&P/TSX Index?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.